A Clinical Trial of KT07 Capsule in the U.S.A

NCT ID: NCT02867358

Last Updated: 2020-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

391 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High dose of KT07 capsule

It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).

Group Type ACTIVE_COMPARATOR

KT07 Capsule

Intervention Type DRUG

Low dose of KT07 capsule

It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).

Group Type ACTIVE_COMPARATOR

KT07 Capsule

Intervention Type DRUG

Placebo

Intervention Type OTHER

Placebo

It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KT07 Capsule

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lianhua Qingwen Capsule

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with acute uncomplicated influenza with oral temperature ≥ 37.8 ℃ (100.04 °F); plus at least one respiratory symptom (nasal congestion, sore throat, cough); and at least one constitutional symptom (aches or pains, fatigue, headache, chills or sweats). If antipyretics were taken, may wait at least 4 hours after dosing to determine if a qualifying temperature is observed.
2. Subjects with RIDT confirmed influenza infection.
3. Onset of symptoms less than 48 hours before Visit 1 (Screening; study drug administration visit). The onset of symptoms is defined as either:

* Time of the first increase in body temperature to ≥ 37.8 ℃ (100.04 °F); or
* Time when the subject experiences at least one general or respiratory symptom.
4. Age 18 to 65 years old.
5. Subjects who are able to understand and willing to sign the informed consent form (ICF).
6. All female subjects of child-bearing potential must have a negative urine pregnancy test result. All female subjects of child-bearing potential and male subjects and their spouse/partner must agree to use a medically acceptable method of contraception (e.g., abstinence, an intrauterine device, a double barrier method such as condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive or have a vasectomized partner with confirmed azoospermia) throughout the entire study period, and for 30 days for females and 90 days for males after study drug discontinuation.

Exclusion Criteria

1. Subjects with severe influenza virus infection requiring inpatient treatment.
2. Subjects with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the time of screening.
3. Subjects who have any of the following documented conditions: uncontrolled hypertension (systolic blood pressure \> 140 mm Hg or diastolic blood pressure \> 90 mm Hg), diabetes, asthma (any current or recent, not childhood if resolved), COPD (any), cardiac, hepatic, renal (including eGFR\<60) and hematopoietic disorders, bleeding tendency or hemorrhagic disease, neurological system disease, compromised immune system (including patients receiving immunosuppressant therapy, or those with cancer within the past 5 years or human immunodeficiency virus \[HIV\] infection), endocrine disorders (including thyroid disorders).
4. Subjects with anatomical nasal obstruction or gross anatomical abnormalities. For example, nasal polyps or significant nasal septal deviation.
5. Clinically obese subjects with BMI≥40.
6. Subjects with recent history (within 1 year) of alcoholism or substance abuse.
7. Received influenza vaccine within 21 days.
8. Participation in other clinical trial within 1 month, or during the study.
9. Pregnant or breast-feeding female subjects
10. Allergy or known allergy to components of study medication.
11. Subjects who took a monoamine oxidase inhibitor (MAOI) within 2 weeks prior to enrollment.
12. Previous history of difficulty swallowing capsules.
13. Any other associated disease or condition which, in the opinion of the investigator, might restrict or impede participation in the study or affect the study results.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yiling Pharmaceutical Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xuedong Gao, MD

Role: STUDY_DIRECTOR

Yiling Pharmaceutical Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Alabama Research

Birmingham, Alabama, United States

Site Status

Parkway Medical Center, LLC

Birmingham, Alabama, United States

Site Status

Cahaba Research, Inc.

Birmingham, Alabama, United States

Site Status

David Wever

Pelham, Alabama, United States

Site Status

Alliane Urgent Care

Tolleson, Arizona, United States

Site Status

Orange County Research Institute

Anaheim, California, United States

Site Status

Hope Clinical Research, Inc.

Canoga Park, California, United States

Site Status

Core Health Care Group

Cerritos, California, United States

Site Status

Aviva Research

Escondido, California, United States

Site Status

Lalla-Reddy Medical Corp.

Fountain Valley, California, United States

Site Status

Research Center of Fresno, Inc.

Fresno, California, United States

Site Status

Ark Clinical Research

Long Beach, California, United States

Site Status

Long Beach Clinical Trials Services, Inc

Long Beach, California, United States

Site Status

Downtown L.A. Research Center, Inc.

Los Angeles, California, United States

Site Status

IMD Medical Group

Los Angeles, California, United States

Site Status

Facey Medical Foundation

Mission Hills, California, United States

Site Status

MD Strategies Research Centers

San Diego, California, United States

Site Status

Empire Clinical Research

Upland, California, United States

Site Status

Cherry Creek Family Practice, PLLC

Denver, Colorado, United States

Site Status

Urgent Care-Denver

Denver, Colorado, United States

Site Status

Clinical Research Consulting

Milford, Connecticut, United States

Site Status

Comprehensive Psychiatric Center

Norwich, Connecticut, United States

Site Status

Doral Medical Research

Doral, Florida, United States

Site Status

Finlay Medical Research Corp.

Miami, Florida, United States

Site Status

Panamerican Health Center, Inc.

Miami, Florida, United States

Site Status

AppleMed Reseach, Inc.

Miami, Florida, United States

Site Status

Research Institute of South Florida, Inc.

Miami, Florida, United States

Site Status

Florida Research Center, Inc.

Miami, Florida, United States

Site Status

Sweet Hope Research Specialty, Inc

Miami Lakes, Florida, United States

Site Status

Sunrise Medical Research

Tamarac, Florida, United States

Site Status

Sunrise Medical Research

West Palm Beach, Florida, United States

Site Status

Southeast Clinical Research

Williston, Florida, United States

Site Status

Invocare (Savannah GA location)

Rincon, Georgia, United States

Site Status

Infinite Clinical Trials

Riverdale, Georgia, United States

Site Status

The Blackfoot Medical Center - Blackfoot

Blackfoot, Idaho, United States

Site Status

Buynak Clinical Research, P.C.

Valparaiso, Indiana, United States

Site Status

Horizon Research Group of Opelousas, LLC

Eunice, Louisiana, United States

Site Status

Centex Studies, Inc

Lake Charles, Louisiana, United States

Site Status

MedPharmics, LLC

Metairie, Louisiana, United States

Site Status

Centennial Medical Group

Elkridge, Maryland, United States

Site Status

MD Medical Research

Oxon Hill, Maryland, United States

Site Status

Romedica LLC

Rochester, Michigan, United States

Site Status

Olive Branch Family Medical Center

Olive Branch, Mississippi, United States

Site Status

Mercury Street Medical Group, PLLC

Butte, Montana, United States

Site Status

Red Rock Clinical Research, LLC

Las Vegas, Nevada, United States

Site Status

Hassman Research Institute

Berlin, New Jersey, United States

Site Status

AccuMed Research Associates

Garden City, New York, United States

Site Status

New York Clinical Trials

Manhattan, New York, United States

Site Status

Carolina Research Center, Inc

Shelby, North Carolina, United States

Site Status

Ardmore Family Practice

Winston-Salem, North Carolina, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

META Medical Research Institute, LLC

Dayton, Ohio, United States

Site Status

Medical Research International

Oklahoma City, Oklahoma, United States

Site Status

Detweiler Family Medicine

Lansdale, Pennsylvania, United States

Site Status

Frontier Clinical Research, LLC

Scottdale, Pennsylvania, United States

Site Status

Frontier Clinical Research, LLC

Smithfield, Pennsylvania, United States

Site Status

American Family Care Urgent Care

Chattanooga, Tennessee, United States

Site Status

Clinical Research Solutions, LLC

Franklin, Tennessee, United States

Site Status

Clinical Research Solutions, LLC

Jackson, Tennessee, United States

Site Status

Clinical Research Solutions, LLC

Nashville, Tennessee, United States

Site Status

Clinical Research Solutions, LLC

Smyrna, Tennessee, United States

Site Status

Clinical Research Solutions, LLC

Spring Hill, Tennessee, United States

Site Status

Premier Family Physicians

Austin, Texas, United States

Site Status

Pioneer Research Solutions

Beaumont, Texas, United States

Site Status

Family Medicine Associates of Texas

Carrollton, Texas, United States

Site Status

Corpus Christi Family Wellness

Corpus Christi, Texas, United States

Site Status

Northwest Med Care

Cypress, Texas, United States

Site Status

City Doc Urgent Care

Dallas, Texas, United States

Site Status

Centex Studies, Inc.

Houston, Texas, United States

Site Status

Centex Studies, Inc.

McAllen, Texas, United States

Site Status

Village Health Partners

Plano, Texas, United States

Site Status

Quaity Assurance Research Center

San Antonio, Texas, United States

Site Status

Bandera Family Health Clinic

San Antonio, Texas, United States

Site Status

Wade Family Medicine

Bountiful, Utah, United States

Site Status

J. Lewis Research, Inc./ Foothill Family Clinic Draper

Draper, Utah, United States

Site Status

J. Lewis Research, Inc. / Foothill Family Clinic

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc. / Foothill Family Clinic South

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc./ FirstMed East

Salt Lake City, Utah, United States

Site Status

CopperView Medical Center

South Jordan, Utah, United States

Site Status

Chrysalis Clinical Research

St. George, Utah, United States

Site Status

Clinical Research Partners

Richmond, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KT07-US-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Severe Influenza A Infection
NCT02108366 COMPLETED PHASE3